The effect of phosphorolcoline-coated cardiopulmonary by-pass circuits on morbidity and mortality in patients with congenital open cardiac surgery

Abstract

Objective: Our aim in this study is to investigate the relationship between mortality and morbidity of phosphorylcholine coated oxygenator circuit used in heart-lung machine in congenital open heart surgery operations. Materials and Methods: The study was conducted in Dr. Sami Ulus Child Diseases Training and Research Hospital Cardiovascular Surgery Clinic between 2008-2009. 30 congenital heart patients were included. The patients were divided into 2 groups of 15 people. In one of the groups, a phosphorylcholine coated oxygenator circuit was used in the heart lung machine (Group P). In the other group, a standard oxygenator circuit was used (Group C).Congenital heart surgery was performed for 19 Ventricular Septal Defects (VSD), 5 Secundum Atrial Septal Defects (ASD), 3 Primum ASD, 2 Mitral insufficiency and 1 Discret subaortic membrane. Extubation times, intensive care and discharge times, 24-hour drainage follow-up, inotropic drug use, blood and fresh frozen plasma (FFP) transfusion amount, aspartate aminotransferase, alanine aminotransferase, creatine phosphokinase-MB, urea, blood urea nitrogen, creatinine, white cell number of platelets, lactate dehydrogenase, albumin, total protein, C-reactive protein, prothrombin time, partial thromboplastin time, fibrinogen, D-dimer, C5a and elastase levels were compared perioperatively. Results: In the study, it was determined that the discharge time was shorter in Group P. It was found that the increase in d-dimer values with fibrinogen was less in Group P. These were found to be statistically significant (p <0.05). There was no significant difference between groups in other parameters (p> 0.05). There was no mortality in either group. Conclusion: In this study, phosphorylcholine-coated oxygenator did not significantly reduce the inflammatory response during cardiopulmonary by-pass (CPB). There was no difference between the two groups in terms of morbitidity and mortality.However, the fact that fibrinogen values, which are the acute phase reactants, are lower than the control group and the increase in d-dimer values remain limited may be important in terms of hemocompatibility of the phosphorylcholine coated circuit.

Keywords

• Phosphorylcholine coated oxygenator
• congenital heart surgery
• cardiopulmonary bypass
• inflammation

Project Number

YOK

References

1. Zahler S, Massoudy P, Hartl H, Hähnel C, Meisner H, Beckeret BF. Acute cardiac inflammatory responses to post ischemic reperfusion during cardiopulmonary bypass. Cardiovasc Res 1999; 41: 722-30.
2. Gemalmaz H, Gültekin Y, Hasanov Y. Yurtdışında yeni kurulan kalp merkezindeki sonuçlar. AJHM 2020; 3: 11-7.
3. Siregar S, Groenwold RHH, De Mol BAJM, et al. Evaluation of cardiac surgery mortality rates: 30-day mortality or longer follow up? Eur J Cardio Thoracic Surg. 2013; 44: 875-83.
4. McGiffin DC, Kirklin Ki. Cardiopulmonary bypass forcardiacsurgery. in Sabiston DC, Spencer FC. Surgerythe Chest. 61h ed, yol II, Philadelphia: WB Saunders, 1256-71, 1995.
5. Brix-Christensen V. The systemic inflammatory response after cardiac surgery with cardiopulmonary bypass in children. Acta Anaesthesiol Scand. 2001;/45:/671-9.
6. Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. AnnThoracSurg 1993; 55: 552-9.
7. Casey LC. Role of cytokines in thepathogenesis of cardiopulmonary induced multisystem organ failure. Ann Thorac Surg 1993; 56: 92-6.
8. Walport MJ. Complement. N Engl J Med 2001; 344: 1058.

9. Mansuroğlu D, Kirali K, Yakut C. Kardiyopulmoner bypass sırasındaki enflamatuvar yanıt: hücresel yanıt, enflamasyonun diğer mediyatörleri, akut enflamasyonun kontrolü. Türkiye Klinikleri Kalp Damar Cerrahisi Derg 2004; 5: 183-96.
10. Ilion MK. Langlon PE. Taylor ML, et al. Differentialexpression of neutrophil adhesion molecules during coronary artery surgery with cardiopulmonary bypass. J Thorac Cardiovasc Surg 1999; 118: 930-7.
11. Mair P. Mair J. Seibt I Furtwaengler W, Balogh D. Plasma elastase concentrations and pulmonary function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994; 108: 184-5.
12. Windsor AC, Mullen PG, Fowler AA, Sugerman HJ. Role of theneutrophil in adult respiratory distress syndrome. Br J Surg1993; 80: 10-7.
13. Paparella D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation; pathophysiology and treatment. An update. Eur J Cardiothorac Surg 2002; 21: 232-44.
14. Wan S, Le Clerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass, mechanisms involved and possible therapeutic strategies. Chest 1997; 112: 676-92.
15. Günaydin E. Emerging Technologies in biocompatible surface modifying additives quest for physiologiccardiopulmonary bypass. Curr Med Chem Cardiovasc Hematol Agents 2004; 2: 187-96.
16. De Somer F, François K, vanOeveren W et al. Phosphorylcholine coating of extra corporeal circuits provides natural protection against blood activation by the material surface. Eur J Cardiothorac Surg. 2000; 18: 602-6.
17. VonSegesser LK, Mihaljevic T, Tönz M, Leskosek B, Pei P, Turina M. Heparin surface coated hard shell venous reservoirs: experimental evaluation exvivo. Int J Artif Organs. 1994; 17: 651-56.
18. Larmann J, Theilmeier G. Inflammatory response to cardiac surgery: cardiopulmonary bypass versus non-cardiopulmonary bypass surgery. Best Pract Res Clin Anaesthesiol 2004; 18; 425-38.
19. Kozik DJ, Tweddell JS. Characterizing the inflammatory response to cardiopulmonary bypass in children. Ann Thorac Surg 2006; 81: 2347-54.
20. Boldt J, Osmer C, Linke LC, Dapper F, Hempelmann G. Circulating adhesion molecules in pediatric cardiac surgery. Anesth Analg 1995; 81: 1129-35.
21. Çelebioğlu B, Özer E. Kardiyopulmonerby-pass ve sistemik inflamatuvar yanıt. Hacettepe Tıp Derg 2004; 35: 18-26.
22. Zwaal RFA, Comfurius P, vanDeenen LLM. Membrane assymmetry and blood coagulation. Nature 1977; 268: 358-60.
23. Yianni YP. Biocompatible surfaces based upon biomembrane mimicry. In: Quinn PJ, Cherry RJ, editors. Structuraland Dynamic Properties of Lipids and Membranes, London: Portland Press Ltd, 1992, 187-216.
24. VonSegesser LK, Mihaljevic T, Tönz M Leskosek B, Pei P, Turina M. Heparin surface coated hard Shell venous reservoirs: experimental evaluation exvivo. Int J Artif Organs. 1994; 17: 651-56.
25. Campbell EJ, O'Byrne V, Stratford PW et al. Biocompatible surfaces using methacryloylphosphorylcholine laurylmethacrylate copolymer. ASAIO J 1994; 40: 853-7.
26. Wendel HP, Ziemer G. Coating-techniquestoimprovethehemocompatibility of artificial devices used for extracorporeal circulation. Eur J Cardiothorac Surg. 1999; 16: 342-50.
27. De Somer F, Van Belleghem Y, Foubert L et al. Invivoevaluation of a phosphorylcholine coated cardiopulmonary bypass circuit. J ExtraCorporTechnol. 1999; 31: 62-6.
28. Draaisma AM, Hazekamp MG, Anes N et al. Phosphorylcholinecoating of bypass systems used for young infants does not attenuate the inflammatory response. Ann Thorac Surg. 2006; 81: 1455-9.
29. Pappalardo F, DellaValle P, Crescenzi G et al. Phosphorylcholine coating may limit thrombin formation during high-risk cardiacsurgery: a randomizedcontrolledtrial. Ann Thorac Surg. 2006; 81: 886-91.
30. De SF, Van BY, Caes F, et al. Phosphorylcholine coating offers natural platelet preservation during cardiopulmonary bypass. Perfusion. 2002; 17: 39-44.
31. Kirshbom PM, Miller BE, Spitzer K, et al. Failure of surface-modified bypass circuits to improve platelet function during pediatric cardiac surgery. J Thorac Cardiovasc Surg 2006; 132: 675–80.
32. Zilla P, Fasol R, Groscurth P, Klepetko W, Reichenspurner H, Wolner E. Blood platelets in cardiopulmonary bypass operations. J Thorac Cardiovasc Surg 1989; 97: 379.
33. Harig F, Cesnjevar R, Lindemann Y, Bumiller L, Singer H, WeyandM. Phosphorylcholine-coatedcardiopulmonary bypass in paediatric cardiac surgery improves biocompatibility: reduced contact activation and endothelin-1 release. Critical Care 2001; 5: 14.
34. Bove T, Calabro MG, Landoni G, et al. The incidenceand risk of acute renal failure after cardiac surgery. J Cardiothorac Vasc Anesth 2004; 8: 442-45.
35. Collins JD, Ferner R, Murray A, et al. Incidence and prognostic importance of jaundice after cardiopulmonary bypass surgery. Lancet 1993; 1: 1119.
36. Florens E, Salvi S, Peynet J, et al. Can statins reduce the inflammatory response to cardiopulmonary bypass? A clinicalstudy. J Card Surg 2001; 16: 232-9.